Neurogene Inc.

Neurogene Inc. is a U.S.-based biotechnology company focused on developing gene therapy product candidates for severe neurological diseases. Its pipeline includes programs such as NGN-401 for Rett syndrome and NGN-101 for Batten disease, with research, manufacturing, and clinical development activities centered in the United States.

−100,0 %

16.56

16.56

— Neurogene Inc.
%
Clinical-stage gene therapy programs70% Includes lead and pipeline gene therapy candidates advancing through preclinical and clinical development.
Early discovery programs20% Includes internal discovery work and earlier-stage neurological disease programs not yet in clinical testing.
Licensing and legacy asset monetization10% Includes licensing revenue tied to legacy Neoleukin assets and related agreements.

Neurogene does not currently sell approved products, so its direct economic counterparties are primarily research...

  • Research and development partnersprimary

    Academic and third-party collaborators that support discovery, preclinical work, and clinical execution.

  • Licensing counterpartiessecondary

    Institutions and counterparties involved in licensing biological materials, IP, or legacy assets.

  • Clinical trial ecosystemprimary

    CROs, investigators, and trial sites that enable patient enrollment and study operations.

  • Future commercialization partnersemerging

    Potential licensees or collaborators that could market approved therapies if the company does not commercialize alone.

Neurogene is headquartered in the United States and conducts its core research, development, and manufacturing...

  • •Headquartered in the United States
  • •Core R&D and manufacturing activities are U.S.-based
  • •No disclosed country revenue mix from product sales
  • •Clinical and regulatory exposure is tied to U.S. FDA oversight
  • •Future commercialization could expand beyond the U.S.

Neurogene's strategy is centered on advancing NGN-401 and other neurological gene therapy programs through clinical...

01
Advance lead clinical programsshort-term

Clinical proof-of-concept is the main value driver for a pre-commercial biotech company.

02
Strengthen manufacturing and CMC readinessshort-term

Gene therapy products require specialized process control, supply reliability, and regulatory compliance.

03
Preserve financing flexibilityshort-term

The company depends on external capital to fund ongoing R&D and future commercialization work.

04
Create commercialization optionalitymedium-term

Approved products may be licensed to partners or sold through an internal sales force if built later.

The company faces the typical risks of a clinical-stage biotechnology business: long development timelines, uncertain...

high

Financing risk

Operations are funded primarily through external capital and future funding may be unavailable or costly.

Scope
R&D, clinical trials, and commercialization readiness
Materiality
high
high

Clinical development failure

Product candidates may not demonstrate safety or efficacy in trials.

Scope
NGN-401, NGN-101, and early discovery programs
Materiality
high
high

Regulatory approval risk

FDA or foreign regulators may require additional data or decline approval.

Scope
Clinical and preclinical gene therapy programs
Materiality
high
high

Manufacturing and CMC risk

Biological products require validated processes, stable supply, and specialized controls.

Scope
Drug substance, formulation, and clinical supply production
Materiality
high
medium

Commercialization risk

The company has no sales force or distribution capability and may need partners.

Scope
Future approved products
Materiality
medium
Research and development expense recognition
Quarterly operating loss and comparability
Licensing revenue recognition
Reported revenue can be lumpy and non-recurring
Stock-based compensation
Affects operating expenses and loss metrics
Valuation of acquired licenses and contingencies
Can affect balance sheet values and future expense recognition

NEUROCRINE BIOSCIENCES INC

NBIX · Biological Products, (No Diagnostic Substances)

NEUROONE MEDICAL TECHNOLOGIES Corp

NMTC · Surgical & Medical Instruments & Apparatus

Neuraxis, INC

NRXS · Electromedical & Electrotherapeutic Apparatus

Vistagen Therapeutics, Inc.

VTGN · Pharmaceutical Preparations

JUPITER NEUROSCIENCES, INC.

JUNS · Pharmaceutical Preparations

Protagenic Therapeutics, Inc.\new

PTIX · Pharmaceutical Preparations

: 29.4.2026